Neurogene Inc. (NGNE)
- Previous Close
13.86 - Open
13.80 - Bid 14.43 x 200
- Ask 15.48 x 200
- Day's Range
13.27 - 15.65 - 52 Week Range
6.88 - 74.49 - Volume
181,740 - Avg. Volume
262,300 - Market Cap (intraday)
213.932M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.28 - Earnings Date May 9, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.40
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
www.neurogene.comRecent News: NGNE
View MorePerformance Overview: NGNE
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGNE
View MoreValuation Measures
Market Cap
213.93M
Enterprise Value
-84.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
284.87
Price/Book (mrq)
0.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.50%
Return on Equity (ttm)
-30.28%
Revenue (ttm)
925k
Net Income Avi to Common (ttm)
-75.14M
Diluted EPS (ttm)
-4.28
Balance Sheet and Cash Flow
Total Cash (mrq)
312.4M
Total Debt/Equity (mrq)
4.00%
Levered Free Cash Flow (ttm)
-49.42M